| Bioactivity | Repaglinide-d5 is deuterium labeled Repaglinide. Repaglinide is an insulin secretagogue for the treatment of type-2 diabetes mellitus[1]. | ||||||||||||
| Invitro | Repaglinide reduces postprandial glucose levels by enhancing the early phase of insulin secretion and increasing the total amount of insulin secreted[1]. | ||||||||||||
| Name | Repaglinide-d5 | ||||||||||||
| CAS | 1217709-85-7 | ||||||||||||
| Formula | C27H31D5N2O4 | ||||||||||||
| Molar Mass | 457.62 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Wang LC, et al. Characteristics of repaglinide and its mechanism of action on insulin secretion in patients with newly diagnosed type-2 diabetes mellitus.Medicine (Baltimore). 2018 Sep;97(38):e12476. |
Repaglinide-d5
CAS: 1217709-85-7 F: C27H31D5N2O4 W: 457.62
Repaglinide-d5 is deuterium labeled Repaglinide. Repaglinide is an insulin secretagogue for the treatment of type-2 diab
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.